SynthesisDiabetes, obesity & metabolism2026
The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis.
Synthesis in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis.Diabetes, obesity & metabolism · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsSemaglutide 2.4 mg causes substantial weight loss, but its average effect on patient-reported physical function requires interpretation against clinically meaningful thresholds and routine clinical expectations. This systematic review and meta-analysis aimed to evaluate the effects of once-weekly subcutaneous semaglutide 2.4 mg on patient-reported physical functioning and weight-related quality-of-life outcomes in adults with overweight or obesity. MATERIALS AND
methodsIn this prospectively registered systematic review and meta-analysis, MEDLINE via PubMed, Embase via Elsevier Embase.com, Cochrane CENTRAL, Scopus, and ClinicalTrials.gov were searched for randomised placebo-controlled trials of once-weekly subcutaneous semaglutide 2.4 mg in adults with overweight or obesity reporting SF-36v2 or IWQOL-Lite-CT outcomes. Four STEP trials, including 4182 participants, contributed SF-36v2 Physical Functioning data.
resultsSemaglutide improved SF-36v2 Physical Functioning compared with placebo, with a mean difference of 1.71 points and a 95% confidence interval of 1.07 to 2.35; heterogeneity was moderate, with I
conclusionsThe available randomised evidence comes from the semaglutide development programme. Semaglutide statistically improves patient-reported outcomes, but average functional gains are modest and should be communicated cautiously.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.